Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Xanomeline/Trospium (KarXT) in Alzheimer's Patients on Lecanemab
NCT07212062Phase 2Not yet recruiting
- Sponsor
- Neurology Office of South Florida
- Start
- Dec 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
A Phase 2 trial of xanomeline + trospium chloride in Alzheimer's disease (AD), sponsored by Neurology Office of South Florida. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
xanomeline + trospium chloride
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07212062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07212062.